Abstract | BACKGROUND: METHODS: Patients attending Melbourne Sexual Health Centre between 2017 and 2018 with sexually transmitted infection syndromes were treated with doxycycline for 7 days and recalled if MG-positive. Macrolide-susceptible cases received 2.5 g azithromycin (1 g, then 500 mg daily for 3 days), and resistant cases moxifloxacin (400 mg daily, 7 days). Test of cure was recommended 14-28 days post-antimicrobials. RESULTS: There were 383 patients (81 females/106 heterosexual males/196 men who have sex with men) included. Microbial cure following doxycycline- azithromycin was 95.4% (95% confidence interval [CI], 89.7-98.0) and doxycycline- moxifloxacin was 92.0% (95% CI, 88.1-94.6). De novo macrolide resistance was detected in 4.6% of cases. Combining doxycycline- azithromycin data with our prior RGT study (n = 186) yielded a pooled cure of 95.7% (95% CI, 91.6-97.8). ParC mutations were present in 22% of macrolide-resistant cases. CONCLUSIONS: These findings support the inclusion of moxifloxacin in resistance-guided strategies and extend the evidence for 2.5 g azithromycin and presumptive use of doxycycline. These data provide an evidence base for current UK, Australian, and European guidelines for the treatment of MG.
|
Authors | Duygu Durukan, Tim R H Read, Gerald Murray, Michelle Doyle, Eric P F Chow, Lenka A Vodstrcil, Christopher K Fairley, Ivette Aguirre, Elisa Mokany, Lit Y Tan, Marcus Y Chen, Catriona S Bradshaw |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 71
Issue 6
Pg. 1461-1468
(09 12 2020)
ISSN: 1537-6591 [Electronic] United States |
PMID | 31629365
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected]. |
Chemical References |
- Anti-Bacterial Agents
- Macrolides
- Azithromycin
- Doxycycline
- Moxifloxacin
|
Topics |
- Anti-Bacterial Agents
(pharmacology, therapeutic use)
- Australia
(epidemiology)
- Azithromycin
(therapeutic use)
- Doxycycline
(therapeutic use)
- Drug Resistance, Bacterial
- Female
- Homosexuality, Male
- Humans
- Macrolides
(therapeutic use)
- Male
- Moxifloxacin
- Mycoplasma Infections
(drug therapy)
- Mycoplasma genitalium
- Sexual and Gender Minorities
|